Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes
- PMID:20870345
- DOI: 10.1016/j.ultrasmedbio.2010.07.005
Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes
Abstract
There is a need for noninvasive methods to detect liver steatosis, which can be a factor of liver fibrosis progression. This work aims to evaluate a novel ultrasonic controlled attenuation parameter (CAP) devised to target, specifically, liver steatosis using a sophisticated process based on vibration control transient elastography (VCTE™). CAP was first validated as an estimate of ultrasonic attenuation at 3.5 MHz using Field II simulations and tissue-mimicking phantoms. Performance of the CAP was then appraised on 115 patients, taking the histological grade of steatosis as reference. CAP was significantly correlated to steatosis (Spearman ρ = 0.81, p < 10(-16)). Area under receiver operative characteristic (ROC) curve (AUC) was equal to 0.91 and 0.95 for the detection of more than 10% and 33% of steatosis, respectively. Furthermore, results show that CAP can efficiently separate several steatosis grades. These promising results suggest that CAP is a noninvasive, immediate, objective and efficient method to detect and quantify steatosis.
Copyright © 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.
Similar articles
- Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy.Sasso M, Audière S, Kemgang A, Gaouar F, Corpechot C, Chazouillères O, Fournier C, Golsztejn O, Prince S, Menu Y, Sandrin L, Miette V.Sasso M, et al.Ultrasound Med Biol. 2016 Jan;42(1):92-103. doi: 10.1016/j.ultrasmedbio.2015.08.008. Epub 2015 Sep 19.Ultrasound Med Biol. 2016.PMID:26386476
- Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, Duarte-Rojo A, Wong D, Crotty P, Elkashab M.Myers RP, et al.Liver Int. 2012 Jul;32(6):902-10. doi: 10.1111/j.1478-3231.2012.02781.x. Epub 2012 Mar 21.Liver Int. 2012.PMID:22435761
- How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.Carvalhana S, Leitão J, Alves AC, Bourbon M, Cortez-Pinto H.Carvalhana S, et al.Liver Int. 2014 Jul;34(6):e111-7. doi: 10.1111/liv.12305. Epub 2013 Sep 4.Liver Int. 2014.PMID:24034415
- The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan.Sasso M, Miette V, Sandrin L, Beaugrand M.Sasso M, et al.Clin Res Hepatol Gastroenterol. 2012 Feb;36(1):13-20. doi: 10.1016/j.clinre.2011.08.001. Epub 2011 Sep 15.Clin Res Hepatol Gastroenterol. 2012.PMID:21920839Review.
- Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease.Tamaki N, Kurosaki M, Yasui Y, Tsuchiya K, Izumi N.Tamaki N, et al.J Med Ultrason (2001). 2021 Oct;48(4):481-487. doi: 10.1007/s10396-021-01103-4. Epub 2021 Jun 24.J Med Ultrason (2001). 2021.PMID:34165645Review.
Cited by
- Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Reza Babaei M, Khamseh ME.Taheri H, et al.Adv Ther. 2020 Nov;37(11):4697-4708. doi: 10.1007/s12325-020-01498-5. Epub 2020 Sep 25.Adv Ther. 2020.PMID:32975679Free PMC article.Clinical Trial.
- Assessment of Predictive Factors of Hepatic Steatosis Diagnosed by Vibration Controlled Transient Elastography (VCTE) in Chronic Hepatitis C Virus-Infected Patients.Singh Y, Gogtay M, Gurung S, Trivedi N, Abraham GM.Singh Y, et al.J Community Hosp Intern Med Perspect. 2022 Jul 4;12(4):58-65. doi: 10.55729/2000-9666.1071. eCollection 2022.J Community Hosp Intern Med Perspect. 2022.PMID:36348970Free PMC article.
- Association between Gastroesophageal Reflux Disease and Elastographic Parameters of Liver Steatosis and Fibrosis: Controlled Attenuation Parameter and Liver Stiffness Measurements.Mikolasevic I, Poropat G, Filipec Kanizaj T, Skenderevic N, Zelic M, Matasin M, Vranic L, Kresovic A, Hauser G.Mikolasevic I, et al.Can J Gastroenterol Hepatol. 2021 Feb 23;2021:6670065. doi: 10.1155/2021/6670065. eCollection 2021.Can J Gastroenterol Hepatol. 2021.PMID:33688490Free PMC article.
- Correlation between ZJU index and hepatic steatosis and liver fibrosis in American adults with NAFLD.Luo S, Weng X, Xu J, Lin H.Luo S, et al.Front Med (Lausanne). 2024 Aug 15;11:1443811. doi: 10.3389/fmed.2024.1443811. eCollection 2024.Front Med (Lausanne). 2024.PMID:39211343Free PMC article.
- Cost-utility analysis of nonalcoholic steatohepatitis screening.Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A.Zhang E, et al.Eur Radiol. 2015 Nov;25(11):3282-94. doi: 10.1007/s00330-015-3731-2. Epub 2015 May 21.Eur Radiol. 2015.PMID:25994191Free PMC article.
Publication types
MeSH terms
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous